Efficacy of 10-day melarsoprol schedule 2 years after treatment for late-stage gambiense sleeping sickness

Lancet

Volumn 364, Issue 9436, 2004, Pages 789-790

  Schmid, C ^a   Nkunku, S ^b   Merolle, A ^c   Vounatsou, P ^a   Burri, C ^a  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b Brazzaville   (Congo)

^c Norwegians Peoples Aid   (Angola)

Author keywords

[No Author keywords available]

Indexed keywords

MELARSOPROL;

AFRICAN TRYPANOSOMIASIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SIDE EFFECT; STANDARD; TREATMENT OUTCOME;

EID: 4444384506     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)16940-7     Document Type: Article

References (6)

1. Burri C, Nkunku S, Merolle A, Smith T, Blum J, Brun R. Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Lancet. 355:2000;1419-1425
2. WHO. Control and surveillance of African trypanosomiasis. Report of a WHO Expert Committee, World Health Organ Tech Rep Ser 1998; 92: 829-835.
3. Blackwelder WC. Proving the null hypothesis" in clinical trials. Control Clin Trials. 3:1982;345-353
4. Atherton Skaff PJ, Swan JA. Design and analysis of equivalence clinical trials via the SAS system. http://www.sas.com/proceedings/sugi23/Stats/p218.pdf (accessed July 21, 2004).
5. Ruiz JA, Simarro PP, Josenando T. Control of human African trypanosomiasis in the Quicama focus, Angola. Bull World Health Organ. 80:2002;738-745
6. Legros D, Evans S, Maiso F, Enyaru JCK, Mbulamberi D. Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda. Trans R Soc Trop Med Hyg. 93:1999;439-442